Effect of Post-filter Anticoagulation on Mortality in Patients with Cancer-associated Pulmonary Embolism

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2018 May 19

PMID 29774484

Citations 1

Authors

Jieun Kang

Seon Ok Kim

Yeon-Mok Oh

Sang-Do Lee

Jae Seung Lee

Affiliations

Soon will be listed here.

Abstract

Background: Malignancy is associated with an increased risk of venous thromboembolism. Inferior vena cava filters are a viable alternative when anticoagulation is infeasible because of the risk of bleeding. Although the current guidelines recommend that all patients with a vena cava filter be treated with anticoagulation treatment when the risk of bleeding is reduced, studies concerning the role of concomitant anticoagulation after vena cava filter insertion in high-risk patients are scarce. Since many cancer patients suffer from a high risk of hemorrhagic complications, we aimed to determine the effect of post-filter anticoagulation on mortality in patients with a malignant solid tumor.

Methods: A retrospective cohort study of patients with pulmonary embolism was performed between January 2010 and May 2016. Patients with a solid tumor and vena cava filter inserted because of pulmonary embolism were included. Using Cox proportional hazards model, the prognostic effect of clinical variables was analyzed.

Results: A total of 180 patients were analyzed, with 143 patients receiving and 37 patients not receiving post-filter anticoagulation treatment. Mortality was not significantly different between the two groups. The presence of metastatic cancer and that of pancreatobiliary cancer were significant risk factors for mortality. However, post-filter anticoagulation did not show significant effect on mortality regardless of the stage of cancer.

Conclusion: In patients with cancer-associated pulmonary embolism, the effect of post-filter anticoagulation on mortality may not be critical, especially in patients with a short life expectancy.

Citing Articles

Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study.

Wang B, Jiang C, Zhang Y, Li X, Xu H BMC Cardiovasc Disord. 2022; 22(1):406.

PMID: 36089586 PMC: 9464391. DOI: 10.1186/s12872-022-02849-6.

References

Jimenez D, Aujesky D, Moores L, Gomez V, Lobo J, Uresandi F . Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010; 170(15):1383-9. DOI: 10.1001/archinternmed.2010.199. View

Mandala M, Falanga A, Roila F . Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6:vi85-92. DOI: 10.1093/annonc/mdr392. View

Ray Jr C, Mitchell E, Zipser S, Kao E, Brown C, Moneta G . Outcomes with retrievable inferior vena cava filters: a multicenter study. J Vasc Interv Radiol. 2006; 17(10):1595-604. DOI: 10.1097/01.RVI.0000239102.02956.65. View

Cronin-Fenton D, Sondergaard F, Pedersen L, Fryzek J, Cetin K, Acquavella J . Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010; 103(7):947-53. PMC: 2965880. DOI: 10.1038/sj.bjc.6605883. View

Chow F, Chan Y, Cheung G, Cheng S . Mid- and long-term outcome of patients with permanent inferior vena cava filters: a single center review. Ann Vasc Surg. 2015; 29(5):985-94. DOI: 10.1016/j.avsg.2015.01.009. View

Greenfield L, Proctor M . Recurrent thromboembolism in patients with vena cava filters. J Vasc Surg. 2001; 33(3):510-4. DOI: 10.1067/mva.2001.111733. View

Caine G, Stonelake P, Lip G, Kehoe S . The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002; 4(6):465-73. PMC: 1550339. DOI: 10.1038/sj.neo.7900263. View

Falatko J, Dalal B, Qu L . Impact of Anticoagulation in Elderly Patients With Pulmonary Embolism That Undergo IVC Filter Placement: A Retrospective Cohort Study. Heart Lung Circ. 2017; 26(12):1317-1322. DOI: 10.1016/j.hlc.2017.01.011. View

Blom J, Doggen C, Osanto S, Rosendaal F . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293(6):715-22. DOI: 10.1001/jama.293.6.715. View

10.

Kearon C, Akl E, Comerota A, Prandoni P, Bounameaux H, Goldhaber S . Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e496S. PMC: 3278049. DOI: 10.1378/chest.11-2301. View

11.

Dovrish Z, Hadary R, Blickstein D, Shilo L, Ellis M . Retrospective analysis of the use of inferior vena cava filters in routine hospital practice. Postgrad Med J. 2006; 82(964):150-3. PMC: 2596700. DOI: 10.1136/pgmj.2005.037911. View

12.

Yale S, Mazza J, Glurich I, Peters T, Mukesh B . Recurrent venous thromboembolism in patients with and without anticoagulation after inferior vena caval filter placement. Int Angiol. 2006; 25(1):60-6. View

13.

Charlson M, Sax F, MacKenzie C, Braham R, Fields S, DOUGLAS Jr R . Morbidity during hospitalization: can we predict it?. J Chronic Dis. 1987; 40(7):705-12. DOI: 10.1016/0021-9681(87)90107-x. View

14.

Kamphuisen P, Beyer-Westendorf J . Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res. 2014; 133 Suppl 2:S49-55. DOI: 10.1016/S0049-3848(14)50009-6. View

15.

Heit J, OFallon W, Petterson T, Lohse C, Silverstein M, Mohr D . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162(11):1245-8. DOI: 10.1001/archinte.162.11.1245. View

16.

Kaufman J, Kinney T, Streiff M, Sing R, Proctor M, Becker D . Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006; 17(3):449-59. DOI: 10.1097/01.rvi.0000203418-39769.0d. View

17.

Streiff M, Bockenstedt P, Cataland S, Chesney C, Eby C, Fanikos J . Venous thromboembolic disease. J Natl Compr Canc Netw. 2013; 11(11):1402-29. DOI: 10.6004/jnccn.2013.0163. View

18.

Ray Jr C, Prochazka A . The need for anticoagulation following inferior vena cava filter placement: systematic review. Cardiovasc Intervent Radiol. 2007; 31(2):316-24. DOI: 10.1007/s00270-007-9244-x. View

19.

. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005; 112(3):416-22. DOI: 10.1161/CIRCULATIONAHA.104.512834. View

20.

Stein P, Kayali F, Olson R . Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med. 2004; 164(14):1541-5. DOI: 10.1001/archinte.164.14.1541. View